Foghorn Therapeutics: Director Departure, New Officer, Comp Changes

Ticker: FHTX · Form: 8-K · Filed: May 1, 2025 · CIK: 1822462

Foghorn Therapeutics Inc. 8-K Filing Summary
FieldDetail
CompanyFoghorn Therapeutics Inc. (FHTX)
Form Type8-K
Filed DateMay 1, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: leadership-change, executive-appointment, board-composition

Related Tickers: FHTX

TL;DR

Foghorn Therapeutics shakes up leadership: Epstein out, Johnson in as director, Albeson named CMO.

AI Summary

Foghorn Therapeutics Inc. announced on April 25, 2025, the departure of Director David Epstein and the election of new Director David R. Johnson. The company also appointed Dr. Jeffrey W. Albeson as Chief Medical Officer and updated its compensatory arrangements for certain officers.

Why It Matters

Changes in board composition and key executive appointments can signal shifts in company strategy or operational focus.

Risk Assessment

Risk Level: medium — Changes in key leadership roles and compensatory arrangements can introduce uncertainty regarding future strategic direction and execution.

Key Players & Entities

  • Foghorn Therapeutics Inc. (company) — Registrant
  • David Epstein (person) — Departing Director
  • David R. Johnson (person) — Elected Director
  • Dr. Jeffrey W. Albeson (person) — Appointed Chief Medical Officer
  • April 25, 2025 (date) — Date of earliest event reported

FAQ

Who has departed from Foghorn Therapeutics' board of directors?

David Epstein has departed from Foghorn Therapeutics' board of directors as of April 25, 2025.

Who has been elected as a new director for Foghorn Therapeutics?

David R. Johnson has been elected as a new director for Foghorn Therapeutics.

What is the new role for Dr. Jeffrey W. Albeson?

Dr. Jeffrey W. Albeson has been appointed as the Chief Medical Officer of Foghorn Therapeutics.

What is the exact date of the earliest event reported in this filing?

The earliest event reported in this filing occurred on April 25, 2025.

What is the state of incorporation for Foghorn Therapeutics Inc.?

Foghorn Therapeutics Inc. is incorporated in Delaware.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on May 1, 2025 by David Epstein regarding Foghorn Therapeutics Inc. (FHTX).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.